Publications

Flower CT, Liu C, Chuang H, Ye X, Cheng H, Heath JR, Wei W, White FM. Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition. Cell Syst. 2025 Mar 17:101239.

Latchford LP, Perez LS, Conage-Pough JE, Turk R, Cusimano MA, Vargas VI, Arora S, Shienvold SR, Kulp RR, Belverio HM, White FM, Thévenin AF. Differential substrate specificity of ERK, JNK, and p38 MAP kinases toward connexin 43. J Biol Chem. 2025 Jan 10;301(3):108178.

Hillis AL, Tamir T, Perry GE, Asara JM, Johnson JL, Yaron TM, Cantley LC, White FM, Toker A. Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome. Proc Natl Acad Sci USA. 2024 Nov 19;121(47):e2413837121.

Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, Maiorino L, White FM, Irvine DJ, Litchfield K, Spranger S. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer. 2024 Nov 9;12(11):e010249.

Leddy O, Cui Y, Ahn R, Stopfer L, Choe E, Kim DH, Roerden M, Spranger S, Bryson BD, White FM. Validation and quantification of peptide antigens presented on MHCs using SureQuant. Nat Protoc (2024).

Alkhatib H*, Conage-Pough J*, Chowdhury SR, Shian D, Zaid D, Rubinstein AM, Sonnenblick A, Peretz-Yablonsky T, Granit A, Carmon E, Kohale IN, Boughey JC, Goetz MP, Wang L, White FM**, Kravchenko-Balasha N**. Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer. Mol Cancer. 2024;23(1):17.

Conage-Pough JE*, Stopka SA*, Oh JH, Mladek AC, Burgenske DM, Regan MS, Baquer G, Decker PA, Carlson BL, Bakken KK, Zhang J, Liu L, Sun C, Mu Z, Zhong W, Tran NL, Elmquist WF, Agar NYR, Sarkaria JN, White FM. WSD-0922, a novel brain-penetrant inhibitor of EGFR, promotes survival in glioblastoma mouse models. Neurooncol Adv. 2023;5(1):vdad066.

Gerritsen JS, Faraguna JS, Bonavia R, Furnari FB, White FM. Predictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling network. Life Sci Alliance. 2023;6(8):e202201466.

Leddy O, White FM, Bryson BD. Immunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class I. Elife. 2023;12:e84070.

Stopfer LE*, Rettko NJ*, Leddy O, Mesfin JM, Brown E, Winski S, Bryson B, Wells JA, White FM. MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas. Proc Natl Acad Sci USA. 2022;119(49):e2208900119.

Kohale IN, Yu J, Zhuang Y, Fan X, Reddy RJ, Sinnwell J, Kalari KR, Boughey JC, Carter JM, Goetz MP, Wang L, White FM. Identification of Src family kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer. Cancers. 2022;14(17):4220.

Fessenden TB*, Stopfer LE*, Chatterjee F*, Zulueta J, Mesfin J, Cordero Dumit T, Reijers I, Hoefsmit EP, Blank C, White F, Spranger S. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. J Immunother Cancer. 2022;10(7):e004159.

Lopez BGC*, Kohale IN*, Du Z*, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS, Basu SS, Clark AR, Marin BM, Mladek AC, Burgenske DM, Agar JN, Supko JG, Grossman SA, Nabors LB, Raychaudhuri S, Ligon KL, Wen PY, Alexander B, Lee EQ, Santagata S**, Sarkaria J**, White FM**, Agar NYR**. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022;24(1):64-77.

Stopfer LE, Gajadhar AS, Patel B, Gallien S, Frederick DT, Boland GM, Sullivan RJ, White FM. Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. Proc Natl Acad Sci USA. 2021;118(37):e2111173118.